Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
O60220

UPID:
TIM8A_HUMAN

ALTERNATIVE NAMES:
Deafness dystonia protein 1; X-linked deafness dystonia protein

ALTERNATIVE UPACC:
O60220; B2R5A6; Q6IRW6

BACKGROUND:
The protein Mitochondrial import inner membrane translocase subunit Tim8 A, known for its roles in mitochondrial dynamics, is pivotal in neurologic development. It ensures the proper import and assembly of essential proteins into the mitochondrial inner membrane, thereby maintaining mitochondrial integrity and function. Its activity is crucial for cellular energy homeostasis and the prevention of protein aggregation within the mitochondrial intermembrane space.

THERAPEUTIC SIGNIFICANCE:
Given its critical function in mitochondrial maintenance and its association with Mohr-Tranebjaerg syndrome, Mitochondrial import inner membrane translocase subunit Tim8 A represents a significant target for drug discovery. Exploring its mechanisms further could lead to innovative treatments for mitochondrial disorders and contribute to our understanding of neurodegenerative diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.